Denosumab for the treatment of postmenopausal osteoporosis

Women's Health

Volumn 5, Issue 1, 2009, Pages 15-22

  Lewiecki, E Michael ^a  

^a NEW MEXICO CLINICAL RESEARCH AND OSTEOPOROSIS CENTER   (United States)

Author keywords

AMG 162; Denosumab; FRAX; Osteoporosis; Prevention; Treatment

Indexed keywords

ALENDRONIC ACID; ALKALINE PHOSPHATASE BONE ISOENZYME; AMINO TERMINAL TELOPEPTIDE; ANTIBIOTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; DENOSUMAB; ESTROGEN DERIVATIVE; IBANDRONIC ACID; OSTEOCLAST DIFFERENTIATION FACTOR; PARATHYROID HORMONE[1-34]; PLACEBO; RALOXIFENE; RECOMBINANT PARATHYROID HORMONE; RISEDRONIC ACID; SALCATONIN; STRONTIUM RANELATE; VITAMIN D; ZOLEDRONIC ACID;

ARTICLE; BONE DENSITY; BONE REMODELING; BONE TURNOVER; CLINICAL TRIAL; COMMUNICABLE DISEASE; DIVERTICULITIS; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; HIP FRACTURE; HUMAN; INFECTION; LABYRINTHITIS; MALIGNANT NEOPLASTIC DISEASE; MAXIMUM PLASMA CONCENTRATION; OPPORTUNISTIC INFECTION; OSTEOPENIA; PATIENT COMPLIANCE; PLASMA HALF LIFE; PNEUMONIA; POSTMENOPAUSE OSTEOPOROSIS; RISK REDUCTION; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; VERTEBRA FRACTURE;

AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; BONE DENSITY; CLINICAL TRIALS AS TOPIC; FEMALE; FRACTURES, BONE; HUMANS; MIDDLE AGED; OSTEOCLASTS; OSTEOPOROSIS, POSTMENOPAUSAL; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RANK LIGAND;

EID: 59349115176     PISSN: 17455057     EISSN: 17455065     Source Type: Journal    
DOI: 10.2217/17455057.5.1.15     Document Type: Article

References (32)

1. Klibanski A, Adams-Campbell L, Bassford T. et al.: Osteoporosis prevention, diagnosis, and therapy. JAMA 285(6), 785-795 (2001).
2. Cooper C: The crippling consequences of fractures and their impact on quality of life. Am. J. Med. 103(2A), 12S-19S (1997).
3. Johnell O, Kanis JA, Oden A et al.: Fracture risk following an osteoporotic fracture. Osteoporos. Int. 15(3), 175-179 (2004).
4. Feldstein A, Elmer PJ, Orwoll E, Herson M, Hillier T: Bone mineral density measurement and treatment for osteoporosis in older individuals with fractures - a gap in evidence-based practice guideline implementation. Arch. Intern. Med. 163(18), 2165-2172 (2003).
5. Yood RA, Emani S, Reed JI, Lewis BE, Charpentier M, Lydick E: Compliance with pharmacologic therapy for osteoporosis. Osteoporos. Int. 14(12), 965-968 (2003).
6. Caro JJ, Ishak KJ, Huybrechts KF, Raggio G, Naujoks C: The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporos. Int. 15(12), 1003-1008 (2004).
7. McCombs JS, Thiebaud P, Laughlin-Miley C, 7. Shi J: Compliance with drug therapies for the treatment and prevention of osteoporosis. Maturitas 48(3), 271-287 (2004).
8. US Department of Health and Human Services: Bone Health and Osteoporosis: a report of the Surgeon General. Rockville, MD, US Department of Health and Human Services, Office of the Surgeon General. (2004).
9. Kanis JA; on behalf of the World Health Organization Scientific Group (2007): Assessment of osteoporosis at the primary health-care level. Technical Report. World Health Organization Collaborating Centre for Metabolic Bone Diseases, University of Sheffield, UK (2007).
10. Tosteson AN, Melton LJ III, Dawson-Hughes B et al.: Cost-effective osteoporosis treatment thresholds: the United States perspective. Osteoporos. Int. 19(4), 437-447 (2008).
11. Dawson-Hughes B, Tosteson AN, Melton LJ III et al.: Implications of absolute fracture risk assessment for osteoporosis practice guidelines in the USA. Osteoporos. Int. 19(4), 449-458 (2008).
12. National Osteoporosis Foundation: Clinician's Guide to Prevention and Treatment of Osteoporosis. Washington, DC, National Osteoporosis Foundation (2008).
13. National Osteoporosis Foundation. Physician's Guide to Prevention and Treatment of Osteoporosis. Washington, DC, National Osteoporosis Foundation (2003).
14. Bekker PJ, Holloway DL, Rasmussen AS et al.: A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J. Bone Miner. Res. 19(7), 1059-1066 (2004).
15. Lewiecki EM, Miller PD, McClung MR et al.: Two-year treatment with denosumab (AMG 162) in a randomized Phase 2 study of postmenopausal women with low bone mineral density. J. Bone Miner. Res. 22(12), 1832-1841(2007).
16. McClung MR, Lewiecki EM, Cohen SB et al.: Denosumab in postmenopausal women with low bone mineral density. N. Engl. J. Med. 354(8), 821-831 (2006).
17. Miller PD, Bolognese MA, Lewiecki EM et al.: Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded Phase II clinical trial. Bone 43(2), 222-229 (2008).
18. Bone HG, Bolognese MA, Yuen CK et al.: Effects of denosumab on bone mineral density and bone turnover in postmenopausal women. J. Clin. Endocrinol. Metab. 93(6), 2149-2157 (2008).
19. Cummings SR, McClung MR, Christiansen C et al.: A Phase III study of the effects of denosumab on vertebral, nonvertebral, and hip fracture in women with osteoporosis: results from the FREEDOM trial. J. Bone Miner. Res. 23 (Suppl.), S80 (2008).
20. Lewiecki EM: Denosumab: a promising drug for the prevention and treatment of osteoporosis. Women's Health 2(4), 517-525 (2006).
21. Riggs BL, Parfitt AM: Drugs used to treat osteoporosis: the critical need for a uniform nomenclature based on their action on bone remodeling. J. Bone Miner. Res. 20 (2), 177-184 (2005).
22. Riggs BL, Melton LJ III, O'Fallon WM: Drug therapy for vertebral fractures in osteoporosis: evidence that decreases in bone turnover and increases in bone mass both determine antifracture efficacy. Bone 18 (Suppl. 3), 197S-201S (1996).
23. McClung MR, San MJ, Miller PD et al.: Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass. Arch. Intern. Med. 165(15), 1762-1768 (2005).
24. Meunier PJ, Slosman DO, Delmas PD et al.: Strontium ranelate: dose-dependent effects in established postmenopausal vertebral osteoporosis - a 2-year randomized placebo controlled trial. J. Clin. Endocrinol. Metab. 87(5), 2060-2066 (2002).
25. Felsenberg D, Boonen S: The bone quality framework: determinants of bone strength and their interrelationships, and implications for osteoporosis management. Clin. Ther. 27(1), 1-11 (2005).
26. Boyle WJ, Simonet WS, Lacey DL: Osteoclast differentiation and activation. Nature 423(6937), 337-342 (2003).
27. Collin-Osdoby P: Regulation of vascular calcification by osteoclast regulatory factors RANKL and osteoprotegerin. Circ. Res. 95(11), 1046-1057 (2004).
28. Simonet WS, Lacey DL, Dunstan CR et al.: Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89(2), 309-319 (1997).
29. Hofbauer LC, Schoppet M: Clinical implications of the osteoprotegerin/ RANKL/RANK system for bone and vascular diseases. JAMA 292(4), 490-495 (2004).
30. Peterson MC, Stouch BJ, Martin SW, Miller PD, McClung MR, Fitspatrick L: The pharmacokinetics of denosumab (AMG 162) following various multiple subcutaneous dosing regimens in postmenopausal women with low bone mass. J. Bone Miner. Res. 20(Suppl. 1), S293 (2005).
31. Brown JP, Prince RL, Deal C et al.: Comparison of the effect of denosumab and alendronate on bone mineral density and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, Phase 3 trial. J. Bone Miner. Res. DOI: 10.1359/jbmr.080910 (2008)
32. Kendler DL, Benhamou CL, Brown JP et al.: Effects of denosumab vs alendronate on bone mineral density (BMD), bone turnover markers (BTM), and safety in women previously treated with alendronate. J. Bone Miner. Res. 23(Suppl.), S473 (2008).